Meta-analysis on peginterferon plus ribavirin in treatment of hepatitis C virus genotype 1 or 4 infection in HIV patients

• Published in: Zhejiang da xue xue bao. Journal of Zhejiang University. Medical sciences. Yi xue ban Vol. 38; no. 3; p. 315
• Main Authors: Zhao, Si-Hai, Liu, En-Qi, Cheng, Da-Xin, Xue, Xin, Chu, Yong-Lie
• Format: Journal Article
• Language: Chinese
• Published: China 01.05.2009
• Subjects: Adult; Antiviral Agents - administration & dosage; Drug Therapy, Combination; Female; Genotype; Hepacivirus - classification; Hepacivirus - genetics; Hepatitis C, Chronic - complications; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - virology; HIV Infections - complications; HIV Infections - drug therapy; HIV Infections - immunology; Humans; Interferon alpha-2; Interferon-alpha - administration & dosage; Male; Polyethylene Glycols - administration & dosage; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin - administration & dosage
• ISSN: 1008-9292

To perform a Meta-analysis on peginterferon with interferon in treatment of HIV patients coinfected with refractory genotype HCV. A literature search of Medline was conducted to identify eligible randomized controlled trials. Meta analysis was conducted to evaluate peginterferon and interferon in treatment of coinfected HCV genotype 1 or 4 in HIV patients. Six trials of 88 matched the selection criteria. Total 1,131 patients with coinfection of HCV genotype 1 or 4 and HIV were included. Sustain viral response was higher in patients treated with peginterferon plus ribavirin compared with that of interferon plus ribavirin (26 % compared with 8 %) or peginterferon alone (26 % compared with 13 %). Severe adverse effects and withdrawal rates were similar for patients treated with peginterferon and patients treated with interferon. Peginterferon plus ribavirin in treatment of patients with coinfection of genotype 1 or 4 HCV and HIV can achieve higher sustain viral response and the likelihoods of serious adverse eff